Recombinant Virus Encoding One Or More Heterologous Proteins Or Fragments Thereof Patents (Class 424/199.1)
  • Patent number: 11345928
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 31, 2022
    Assignees: Arizona Board of Regents, Conseju Superior De Investigaciones Cientificas, IPPOX Foundation
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias El Haddad, James Tartaglia
  • Patent number: 11312760
    Abstract: The present disclosure provides recombinant expression vectors expressing a novel neutralizing antibodies against SARS-COV-2, or the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: April 26, 2022
    Assignee: NEWSOARA BIOPHARMA CO., LTD.
    Inventors: Yuannian Li, Wenyi Wang
  • Patent number: 11305015
    Abstract: CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV are provided. Immunization with CMV vectors having the described features allows selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: April 19, 2022
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • Patent number: 11268071
    Abstract: The present invention provides an efficient process for culturing viruses in the presence of an endonuclease and for producing vaccines, typically from live attenuated viruses, under conditions to reduce the presence of host cell DNA and eliminate the need for a post-harvest DNA digestion step.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: March 8, 2022
    Assignee: Merck Sharp and Dohme Corp.
    Inventors: Yi Li, Matthew Woodling, Adam Kristopeit
  • Patent number: 11268959
    Abstract: Methods, compositions, devices, and kits are described herein that are useful for detecting BoHV-1 infection in animals and/or for distinguishing animals that may benefit from administration of BoHV-1 tmv vaccine.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: March 8, 2022
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventor: Shafiqul Islam Chowdhury
  • Patent number: 11260363
    Abstract: The present invention provides a formulation to link protein to a solid support that comprises one or more proteins, Oligo-dT and one or more non-volatile, water-soluble protein solvents, solutes or combination thereof in an aqueous solution. Further provided is a method of attaching a protein to a surface of a substrate. The formulations provided herein are contacted onto the substrate surface, printed thereon and air dried. The substrate surface is irradiated with UV light to induce thymidine photochemical crosslinking via the thymidine moieties of the Oligo-dT.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: March 1, 2022
    Assignee: PURE TRANSPLANT SOLUTIONS L.L.C.
    Inventor: Michael E. Hogan
  • Patent number: 11242509
    Abstract: Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVA?C7L and VACV?C7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVA?C7L or VACV?C7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: February 8, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Liang Deng, Stewart Shuman, Ning Yang, Taha Merghoub, Jedd Wolchok
  • Patent number: 11229698
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express foreign antigens from three or more avian viruses, along with methods of the use of the multivalent poultry virus vaccines.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: January 25, 2022
    Assignee: Intervet Inc.
    Inventors: Stephanie M. Cook, Mohamad Morsey, Ian Tarpey
  • Patent number: 11174322
    Abstract: The present invention relates to the treatment of HCMV relates diseases. The inventors conducted a study to find an essential domain of pUL56 for its interaction with pUL89 which is important in the effect of the CMV. Sequences alignments allowed them to predict one sequence in C-terminal of pUL56 potentially necessary for interaction with pUL89. BAC mutagenesis and AlphaLISA technologies using purified proteins allowed to validate that the short sequence 671WMVVKYMGFF680 (SEQ ID NO: 1) in C-terminal of pUL56 is involved in interaction with pUL89. Knowing this important information, antibodies directed against this sequence or peptides derived from this sequence could be useful to invalidate the interaction of pUL56 to pUL89 and thus to treat HCMV related diseases.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 16, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), CENTRE HOSPITALIER Régional Universitaire de Limoges, Universitéde Limoges
    Inventors: Sophie Alain, Gaëtan Ligat, Sébastien Hantz, Anthony Couvreux
  • Patent number: 11168307
    Abstract: The invention provides a recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses DNA encoding a heterologous or exogenous antigen, epitope or immunogen and Flagellin or an operable binding portion thereof. The poxvirus can contain or be engineered to contain and express vaccinia host range gene K1L. The poxvirus can be attenuated as to mammals, e.g., NYVAC, NYVAC.1, NYVAC.2, avipox, canarypox, fowlpox, ALVAC, TROVAC, MVA, or MVA-BN. The invention also provides methods for inducing an immunological response involving the poxvirus, and compositions containing the poxvirus. The antigen, epitope or immunogen that the poxvirus expresses can be at least one Plasmodium antigen. The Plasmodium antigen(s), epitope(s) or immunogen(s) can be SERA, ABRA, Pfhsp70, AMA-1, Pfs25, Pfs16, CSP, PfSSP2, LSA-1 repeatless, MSA-1, AMA-1 or combination(s) thereof.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: November 9, 2021
    Assignee: V-CORE TECHNOLOGIES, INC.
    Inventors: Enzo Paoletti, Randall L. Weinberg, Scott J. Goebel
  • Patent number: 11154610
    Abstract: The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: October 26, 2021
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Janet K. Yamamoto
  • Patent number: 11065320
    Abstract: The invention relates to a kit comprising at least a first composition and a second composition, each said first and second compositions comprising at least one epitope of a liver disease antigen, wherein said epitope is a CD8+T cell epitope, for use in induction of an immune response in the liver of a mammalian subject by administration of said first composition by intramuscular (i.m.), subcutaneous (s.c.), intradermal (i.d.) or aerosol route, and administration of said second composition by intravenous (i.v.) or subcutaneous (s.c.) route, characterised in that said first and second compositions are administered by different routes. The invention also relates to uses, methods and treatments.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: July 20, 2021
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Adrian V. S. Hill, Anita Gola, Adam Walters, Alexandra Spencer
  • Patent number: 11052148
    Abstract: The compositions and methods are described for generating an immune response to a hepatitis B virus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a hepatitis B virus, in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by hepatitis B virus.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 6, 2021
    Assignees: Geo Vax, Inc., The Georgia State University Research Foundation
    Inventors: Farshad Guirakhoo, Arban Domi, Nathanael P. McCurley, Rahul Basu, Ming Luo
  • Patent number: 11027006
    Abstract: Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: June 8, 2021
    Assignee: VAXum, LLC
    Inventors: Albert B. Deisseroth, Lixin Zhang
  • Patent number: 11013798
    Abstract: The present invention is directed to novel vaccine delivery platform based on the Orf virus (ORFV) genome, which carry heterologous antigens, methods of making and methods of using the same for prevention of infections, diseases, and other conditions in animals.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: May 25, 2021
    Assignees: South Dakota Board of Regents, Federal University of Santa Maria
    Inventors: Diego G. Diel, Eduardo F. Flores
  • Patent number: 10905759
    Abstract: The present invention relates to a composition for raising an immune response in animal which decreases the risk of chikungunya and smallpox infection, Zika virus and smallpox infection, and/or chikungunya, Zika virus and smallpox infection. The composition comprises a pharmaceutically acceptable carrier and an attenuated poxvirus, wherein the poxvirus genome comprises a nucleic acid sequence encoding the 26S subgenomic polyprotein of chikungunya virus and/or the PrME of Zika virus.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: February 2, 2021
    Assignee: SEMENTIS LIMITED
    Inventor: Paul Howley
  • Patent number: 10864263
    Abstract: Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: December 15, 2020
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center. Inc.
    Inventors: Dan Barouch, Macaya Julie Douoguih, Gaston Rafael Picchio
  • Patent number: 10781254
    Abstract: The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and artritic conditions such as RA.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: September 22, 2020
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Randolph J. Noelle, Lili Wang
  • Patent number: 10772953
    Abstract: Disclosed are recombinant spike ectodomain proteins, compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the recombinant proteins, compositions, vectors, kits, and methods relate to, include, and/or utilize a soluble, multimerized form of the (IBV) spike (S) protein ectodomain. The recombinant proteins, compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: September 15, 2020
    Assignee: Auburn University
    Inventors: Vicky L. van Santen, Haroldo E. Toro
  • Patent number: 10729757
    Abstract: Novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof are described, and the pre-fusion RSV F protein contains the amino acid sequence of SEQ ID NO: 1 or 2. Use of the nucleic acid molecules, or vectors containing the nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV) is also described.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: August 4, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Janneke M. Verhagen
  • Patent number: 10702599
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 10702591
    Abstract: The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-,8-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: July 7, 2020
    Assignee: Panacea Pharmaceuticals, Inc.
    Inventors: Biswajit Biswas, Carl R. Merril, Hossein Ghanbari
  • Patent number: 10653769
    Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: May 19, 2020
    Assignee: MEDIGEN, INC.
    Inventors: Peter Pushko, Igor Lukashevich
  • Patent number: 10590435
    Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 17, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Guangping Gao, James M. Wilson, Mauricio R. Alvira
  • Patent number: 10576143
    Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 3, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
  • Patent number: 10548972
    Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: February 4, 2020
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Xuke Zhang, Jinzhong Sun, Feifei Tan
  • Patent number: 10543269
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: January 28, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Patent number: 10532099
    Abstract: Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: January 14, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • Patent number: 10525127
    Abstract: The present invention Provides composition and method for stimulating immune responses against antigens without using conventional adjuvants (such as aluminum salt adjuvants, oil-in-water emulsion adjuvants, toll-like receptor agonist adjuvants, and the like). The composition contains p14.7 protein and an antigen to which the stimulated illumine responses are desired. The p14.7 protein functions as an adjuvant so that the immune responses to the antigen stimulated by the composition comprising p14.7 protein and the antigen are greater than the immune responses stimulated by the antigen alone. The current invention also provides a method for producing thermostable vaccines and a simple strategy for avoiding vaccine cold-chain maintenance by lyophilization.
    Type: Grant
    Filed: March 31, 2018
    Date of Patent: January 7, 2020
    Assignee: Femtomab
    Inventor: Wenyun Zhou
  • Patent number: 10517943
    Abstract: The present invention relates to liquid formulations of poxvirus, in particular vaccinia virus, stable during storage. Such stable liquid formulations comprise a) a poxvirus, preferably a vaccinia virus, b) a pharmaceutically acceptable buffer, c) a monovalent salt, d) a pharmaceutically acceptable disaccharide or sugar alcohol, and e) a pharmaceutically acceptable chelating agent, wherein the pH of the formulation is comprised between 6.5 and 8.5.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: December 31, 2019
    Assignee: Transgene S.A.
    Inventor: Mélina Chasle
  • Patent number: 10493144
    Abstract: The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 3, 2019
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Justin Widener, Leszlie Woodyard, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage, Lauri Motes-Kreimeyer, Marc Fiorucci
  • Patent number: 10480013
    Abstract: The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing the influenza virus vector, its use for the treatment of cancer patients and methods for producing the influenza virus vaccine.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 19, 2019
    Assignee: BLUE SKY VACCINES GMBH
    Inventors: Thomas Muster, Markus Wolschek
  • Patent number: 10465170
    Abstract: Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an M2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic. Also described herein are vaccines and vaccine compositions comprising the live attenuated mutant pneumoviruses. Vaccine compositions can further comprise a pharmaceutically acceptable carrier, vehicle, excipient, and/or adjuvant. Methods for inducing a protective immune response in a subject against a pneumovirus infection are also described and disclosed.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: November 5, 2019
    Assignees: Ohio State Innovation Foundation, Research Institute at Nationwide Children's Hospital
    Inventors: Mark E. Peeples, Jianrong Li, Hui Cai, Rongzhang Wang
  • Patent number: 10441643
    Abstract: This document provides methods and materials for treating cancer. For example, methods and materials for treating cancer using combinations of antigens are provided. For example, VSV vectors designed to express a GNAQ antigen, a TYRP1 antigen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal (e.g., a human). In some cases, VSV vectors designed to express a BRAF antigen, a TOPO-11a antigen, and a YB-I antigen can be used to reduce the number of cancer cells (e.g., skin melanoma cells) within a mammal (e.g., a human). The composition can comprise less than 50 separate nucleic acid molecules.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignees: Mayo Foundation for Medical Education and Research, University of Leeds
    Inventors: Jose S. Pulido, Richard G. Vile, Timothy J. Kottke, Jill M. Thompson, Rosa Maria Diaz, Christine Marie Pulido, Alan A. Melcher, Peter Selby
  • Patent number: 10434166
    Abstract: Disclosed are compositions and methods comprising a vector and a reverse genetics competent unit. The vector may comprise baculovirus expression vectors, bacmids, vaccinia virus and synthetic vectors and the reverse genetics competent unit may comprise pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: October 8, 2019
    Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Daniel R. Perez, Hongjun Chen
  • Patent number: 10428118
    Abstract: Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: October 1, 2019
    Assignee: Oregon Health & Science University
    Inventors: Klaus Frueh, Scott G. Hansen, Jay Nelson, Louis Picker, Patrizia Caposio
  • Patent number: 10398769
    Abstract: Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA Influenza A of serotype H7N9 alone and in combination with HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: September 3, 2019
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David B. Weiner, Jian Yan
  • Patent number: 10383934
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: August 20, 2019
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, Robert G. Ankenbauer, Jacqueline Gayle Marx, Douglas S. Pearce, Marcia L. Keith
  • Patent number: 10370679
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: August 6, 2019
    Assignees: ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona acting for and on behalf of Ariz, CONSEJO SUPERIOR DE INVESTGACIONES CIENTRIFICAS, IPPOX FOUNDATION
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias El Haddad, James Tartaglia
  • Patent number: 10300132
    Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (PBMC) from at least one chronically infected HBV individual in an 10 in vitroassay.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 28, 2019
    Assignee: Altimmune UK Limited
    Inventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
  • Patent number: 10301600
    Abstract: The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: May 28, 2019
    Assignee: BioVex Limited
    Inventor: Robert S. Coffin
  • Patent number: 10293040
    Abstract: The present invention is directed to pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of Bacillus anthracis. Specifically, it involves the administering of an expression vector alone or in conjunction with a fusion protein. The expression vector has a transcription unit encoding a fusion protein composed of an antigenic factor of Bacillus anthracis attached through a linker to the aminoterminal end of the CD40 ligand. This fusion protein has the ability to generate antibodies which prevents Bacillus anthracis infection in an individual.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 21, 2019
    Assignee: MICROVAX, LLC
    Inventor: Albert B. Deisseroth
  • Patent number: 10279029
    Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 7, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria A. Croyle, Stephen Clay Schafer
  • Patent number: 10273285
    Abstract: The present disclosure relates to fusion proteins that are highly useful for the generation of virus-like particles for the display of membrane spanning proteins. Related embodiments, methods and uses are disclosed.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: April 30, 2019
    Assignee: MORPHOSYS AG
    Inventors: Sebastian Jaeger, Daniela Daubert, Kathrin Goetz
  • Patent number: 10265393
    Abstract: Disclosed are yeast-based immunotherapeutic compositions, human immunodeficiency virus (HIV) antigens, and fusion proteins for the treatment and/or prevention of HIV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HIV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HIV and/or symptoms thereof.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: April 23, 2019
    Assignee: GlobeImmune, Inc.
    Inventors: Thomas H. King, David Apelian
  • Patent number: 10251951
    Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: April 9, 2019
    Assignee: CEVA SANTA ANIMALE
    Inventors: Ayumi Fujisawa, Mayumi Kubomura, Sakiko Saeki, Shuji Saito
  • Patent number: 10201605
    Abstract: The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: February 12, 2019
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Xuke Zhang, Jinzhong Sun, Feifei Tan
  • Patent number: 10188720
    Abstract: The present invention relates recombinant viruses and the uses thereof. More particularly, the invention relates to novel recombinant Marek's disease viruses encoding polypeptide(s) of interest, and their use to express or deliver such polypeptides to animals, particularly poultry. The invention is particularly suited to vaccinate poultry against avian pathogens.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: January 29, 2019
    Assignee: CEVA SANTE ANIMALE
    Inventors: Motoyuki Esaki, Shuji Saitoh, Takanori Sato
  • Patent number: 10188721
    Abstract: The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: January 29, 2019
    Assignee: Merial, Inc.
    Inventors: Justin Widener, Leszlie Woodyard, Leonardo Siger, Douglas Brough, Damodar Ettyreddy, Jason Gall, Duncan McVey, Tom Burrage, Lauri Motes-Kreimeyer, Marc Fiorucci
  • Patent number: 10155930
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: December 18, 2018
    Inventor: Per Sonne Holm